Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2020 07:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee

UBX0101 failed to meet 12-week primary endpointGuidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchangedUNITY to focus senescence programs on ophthalmologic and neurologic...
July 01, 2020 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Provides Updates on Lead Development Programs

– Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 – – First-in-human study for UBX1325 in age-related eye disease expected to commence in 2H 2020 – SOUTH...
March 31, 2020 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101

SAN FRANCISCO, March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
February 25, 2020 06:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Provides Pipeline and Business Updates

– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment – – Topline 12- and 24-week results now expected in 2H 2020 – – First patient dosed in phase 1b study to explore...
October 31, 2019 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Announces First Patient Dosed in Phase 2 Study of UBX0101 in Osteoarthritis of the Knee

SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today...
October 24, 2019 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Announces Upcoming Scientific Presentations at ACR 2019 Annual Meeting

SAN FRANCISCO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
August 07, 2019 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates

SAN FRANCISCO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
June 18, 2019 07:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee

Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain ...